CERN Highlights 2023: Explore how CERN accelerates innovation

At Terapet SA, we are pleased to highlight our successful partnership with CERN, a collaboration that propelled us to the forefront of cancer treatment innovation. Together with our world-class partners, we successfully developed Qualyscan, the world’s first end-to-end quality assurance device for proton and heavy ion therapy.

With the support of external funding for the R&D collaboration with CERN funded by the Innosuisse Innovation Project Fund, Terapet has made significant strides in developing innovative medical devices that utilise CERN’s expertise in scintillating crystals. This collaboration culminated in the creation of Qualyscan, their first product now ready for commercialisation, demonstrating the powerful synergy between high-energy physics and medical innovation.

Link to article: